• Molecular NameFluocinonide
  • SynonymFluocinolide; Fluocinolide acetate; Fluocinolone acetonide acetate; fluocinonide; Fluocinonide [USAN:BAN:INN:JAN]; Fluocinonide Emulsified Base; Fluocinonido [INN-Spanish]; Fluocinonidum [INN-Latin]
  • Weight494.531
  • Drugbank_IDDB01047
  • ACS_NO356-12-7
  • Show 3D model
  • LogP (experiment)3.19
  • LogP (predicted, AB/LogP v2.0)2.97
  • pkaN/A
  • LogD (pH=7, predicted)2.97
  • Solubility (experiment)0.00474 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-4.32
  • LogSw (predicted, AB/LogsW2.0)0.03
  • Sw (mg/ml) (predicted, ACD/Labs)0.02
  • No.of HBond Donors1
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds4
  • TPSA99.13
  • StatusFDA approved
  • AdministrationTopical
  • PharmacologyA potent glucocorticoid steroid used topically as anti-inflammatory agent for the treatment of skin disorders such as eczema. It relieves itching, redness, dryness, crusting, scaling, inflammation, and discomfort.
  • Absorption_valueN/A
  • Absorption (description)The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • Metabollsmhepatic
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySide effects may include acne-like eruptions, burning, dryness, excessive hair growth, infection of the skin, irritation, itching, lack of skin color, prickly heat, skin inflammation, skin loss or softening, stretch marks
  • LD50 (rat)N/A
  • LD50 (mouse)N/A